These functional and quantitative genomic data coupled with the high expression of Sp transcription factors in tumor vs. non-tumor tissue suggests that Sp1, Sp3 and Sp4 are NOA genes and attractive drug targets. This evidence concerns the gene TFF2 and neoplasm.